Endocrine Pharmacology — MCQs

Endocrine Pharmacology Indian Medical PG Practice Questions and MCQs

Question 701: A 50-year-old male with type 2 diabetes is prescribed a new medication to manage his condition. Which drug reduces postprandial hyperglycemia without increasing insulin levels?

A. Metformin
B. Glibenclamide
C. Voglibose (Correct Answer)
D. Pioglitazone

Explanation: ***Voglibose*** - **Voglibose** is an alpha-glucosidase inhibitor that works by delaying the digestion and absorption of carbohydrates in the small intestine. - This mechanism specifically reduces the postprandial rise in blood glucose without directly affecting insulin secretion or sensitivity. *Metformin* - **Metformin** primarily reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. - It does not specifically target postprandial hyperglycemia by delaying carbohydrate absorption to the extent that alpha-glucosidase inhibitors do, nor does it increase insulin levels. *Glibenclamide* - **Glibenclamide** is a sulfonylurea that stimulates insulin release from pancreatic beta cells. - This mechanism directly increases insulin levels, which is contrary to the question's premise. *Pioglitazone* - **Pioglitazone** is a thiazolidinedione (TZD) that improves insulin sensitivity in adipose tissue, muscle, and liver. - While it helps manage blood glucose, its primary action is not to reduce postprandial hyperglycemia without altering insulin levels; rather, it improves the body's response to existing insulin.

Question 702: What is the initial pharmacological treatment for a postmenopausal woman diagnosed with osteoporosis?

A. Calcium and vitamin D supplements
B. Bisphosphonates (Correct Answer)
C. Calcitonin
D. Selective estrogen receptor modulators (SERMs)

Explanation: ***Bisphosphonates*** - **Bisphosphonates** are considered the **first-line pharmacological treatment** for most patients with osteoporosis due to their proven efficacy in reducing fracture risk. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Calcium and vitamin D supplements* - While essential for **bone health** and often prescribed alongside other treatments, **calcium and vitamin D supplements** alone are generally not sufficient as the **initial pharmacological treatment** for established osteoporosis. - They are considered foundational support but do not have the same **fracture risk reduction** efficacy as bisphosphonates for patients with diagnosed osteoporosis. *Calcitonin* - **Calcitonin** is a therapeutic option for osteoporosis, but it is typically reserved for patients who cannot tolerate other treatments or for short-term pain relief from acute vertebral fractures. - Its efficacy in reducing non-vertebral fractures is less robust compared to bisphosphonates, making it a **second-line or alternative agent**. *Selective estrogen receptor modulators (SERMs)* - **SERMs** (e.g., raloxifene) are used in osteoporosis treatment, particularly when there is a need to also address **breast cancer risk**. - While effective in preventing vertebral fractures, they are generally **not the first-line choice** for overall fracture prevention, and bisphosphonates are preferred for initial broad-spectrum management of osteoporosis.

Question 703: A patient is diagnosed with hyperthyroidism and prescribed a drug that inhibits thyroid hormone synthesis. Which drug is appropriate in this case?

A. Levothyroxine
B. Methimazole (Correct Answer)
C. Propranolol
D. Amiodarone

Explanation: ***Methimazole*** - **Methimazole** is an **antithyroid drug** that inhibits the synthesis of thyroid hormones by interfering with the organification of iodine and coupling of iodotyrosines. - It is a first-line treatment for **hyperthyroidism** and is effective in reducing excessive thyroid hormone production. *Levothyroxine* - **Levothyroxine** is a **synthetic thyroid hormone (T4)** used to treat **hypothyroidism**, not hyperthyroidism. - Administering levothyroxine to a patient with hyperthyroidism would worsen their condition by increasing thyroid hormone levels. *Propranolol* - **Propranolol** is a **beta-blocker** used to manage the symptomatic effects of hyperthyroidism, such as **tachycardia**, **tremors**, and **anxiety**. - It does not inhibit thyroid hormone synthesis but rather blocks the effects of excess thyroid hormones on target organs. *Amiodarone* - **Amiodarone** is an antiarrhythmic drug that contains iodine, and it can cause **thyroid dysfunction**, including both **hypothyroidism** and **hyperthyroidism**, due to its iodine content and direct toxic effects on the thyroid. - It does not inhibit thyroid hormone synthesis and is not used as a primary treatment for hyperthyroidism.

Question 704: Which oral hypoglycemic drug improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) in type 2 diabetes?

A. Glibenclamide
B. Pioglitazone
C. Metformin (Correct Answer)
D. Acarbose

Explanation: ***Metformin (Correct)*** - **Metformin** is a biguanide that primarily lowers blood glucose by activating **AMP-activated protein kinase (AMPK)**. - This activation improves **insulin sensitivity**, reduces hepatic glucose production, and decreases intestinal glucose absorption. - Metformin is the first-line oral agent for type 2 diabetes and works through AMPK-dependent mechanisms. *Glibenclamide (Incorrect)* - **Glibenclamide** is a sulfonylurea that stimulates insulin secretion from beta cells by blocking **ATP-sensitive potassium channels**. - It does not primarily improve **insulin sensitivity** or activate AMPK. - It works by increasing insulin release, not improving insulin action. *Pioglitazone (Incorrect)* - **Pioglitazone** is a thiazolidinedione (TZD) that improves **insulin sensitivity** by activating **peroxisome proliferator-activated receptor-gamma (PPAR-γ)** in adipose tissue. - While it enhances insulin sensitivity, its mechanism of action is distinct from AMPK activation. - This is an important distractor as it also improves insulin sensitivity but through a different pathway. *Acarbose (Incorrect)* - **Acarbose** is an alpha-glucosidase inhibitor that reduces post-prandial glucose levels by delaying carbohydrate digestion and absorption in the intestine. - It does not directly improve **insulin sensitivity** or act via the AMPK pathway. - It works by slowing glucose absorption, not by improving cellular insulin response.

Question 705: A 30-year-old woman inquires about the mechanism of action of oral contraceptive pills (OCPs). What is the PRIMARY mechanism by which OCPs prevent pregnancy?

A. They inhibit ovulation (Correct Answer)
B. They increase uterine contractility
C. They alter the pH of the vagina
D. They promote the thickening of cervical mucus

Explanation: ***They inhibit ovulation*** - Oral contraceptive pills (OCPs) primarily act by suppressing the **hypothalamic-pituitary-ovarian axis**, preventing the surge of **luteinizing hormone (LH)** required for ovulation. - The **estrogen and progestin** components in OCPs provide negative feedback, leading to inconsistent follicular development and the absence of a dominant follicle. *They increase uterine contractility* - OCPs generally **decrease uterine contractility** to prevent implantation, rather than increase it in a way that would expel a pregnancy. - Increased uterine contractility could potentially interfere with implantation, but this is not the primary mechanism of action of OCPs for preventing conception. *They alter the pH of the vagina* - OCPs do **not significantly alter the vaginal pH** as a primary mechanism for preventing pregnancy. - Changes in vaginal pH are more commonly associated with methods like spermicides or natural physiological variations, not hormonal contraception. *They promote the thickening of cervical mucus* - While OCPs do cause the **thickening of cervical mucus**, making it difficult for sperm to penetrate and reach the egg, this is a **secondary mechanism**. - The **primary and most effective mechanism** is the inhibition of ovulation.

Question 706: What is the mechanism of action of bisphosphonates in the treatment of osteoporosis?

A. Inhibit osteoclast activity (Correct Answer)
B. Enhance calcium absorption
C. Stimulate osteoblast activity
D. Increase parathyroid hormone levels

Explanation: ***Inhibit osteoclast activity*** - Bisphosphonates are analogs of **pyrophosphate** that bind to **hydroxyapatite crystals** in the bone matrix. - Once internalized by osteoclasts during bone resorption, they disrupt the **mevalonate pathway**, leading to osteoclast apoptosis and reduced bone breakdown. *Enhance calcium absorption* - This is primarily the role of **Vitamin D**, which promotes calcium uptake from the gut. - Bisphosphonates do not directly affect **intestinal calcium absorption**. *Stimulate osteoblast activity* - Drugs like **teriparatide** (a parathyroid hormone analog) are known to stimulate osteoblast function and new bone formation. - Bisphosphonates primarily act to reduce bone resorption, not directly stimulate **bone formation**. *Increase parathyroid hormone levels* - **Parathyroid hormone (PTH)** plays a key role in calcium homeostasis, and chronically elevated PTH can lead to bone resorption. - Bisphosphonates do not increase PTH levels; instead, they work independently to strengthen bone.

Question 707: Which antidiabetic drug works by increasing insulin sensitivity through the activation of the peroxisome proliferator-activated receptor-gamma (PPAR-γ)?

A. Glibenclamide
B. Metformin
C. Acarbose
D. Pioglitazone (Correct Answer)

Explanation: ***Pioglitazone*** - **Pioglitazone** is a **thiazolidinedione (TZD)** that exerts its effects by activating **PPAR-γ** receptors. - Activation of **PPAR-γ** leads to increased **insulin sensitivity** in peripheral tissues and the liver, reducing insulin resistance. *Glibenclamide* - **Glibenclamide** is a **sulfonylurea** that works by stimulating **insulin secretion** from pancreatic **beta cells**. - It binds to the **sulfonylurea receptor 1 (SUR1)** on the **ATP-sensitive potassium channel**, causing depolarization and insulin release, not increased insulin sensitivity. *Metformin* - **Metformin** is a **biguanide** that primarily reduces **hepatic glucose production** and slightly increases peripheral glucose uptake. - Its main mechanism involves activation of **AMP-activated protein kinase (AMPK)**, not **PPAR-γ**. *Acarbose* - **Acarbose** is an **alpha-glucosidase inhibitor** that delays the digestion and absorption of carbohydrates in the gastrointestinal tract. - It reduces postprandial glucose excursions by interfering with carbohydrate breakdown, rather than affecting insulin sensitivity directly.

Question 708: What is the first-line drug for osteoporosis in postmenopausal women?

A. OCP
B. Bisphosphonates (Correct Answer)
C. Raloxifene
D. Strontium

Explanation: ***Bisphosphonates*** - **Bisphosphonates** are the **first-line treatment** for osteoporosis due to their proven efficacy in reducing fracture risk by inhibiting osteoclast activity. - They bind to bone mineral and are internalized by osteoclasts, leading to their **apoptosis** and decreased bone resorption. *OCP* - **Oral contraceptives (OCP)** are not used for treating established osteoporosis; they may have a minor protective effect against bone loss in premenopausal women but are not a primary therapeutic agent postmenopause. - OCPs primarily contain **estrogen and/or progestin** and are used for contraception and managing menstrual irregularities. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that can be used for osteoporosis prevention and treatment, especially if there's a concern for breast cancer, but it is typically a second-line option. - Although it mimics estrogen's beneficial effects on bone, it does not have the same overall fracture reduction efficacy as bisphosphonates and can increase the risk of **venous thromboembolism**. *Strontium* - **Strontium ranelate** is an anti-osteoporotic agent that both inhibits bone resorption and promotes bone formation. - Its use has been limited due to concerns about serious side effects, including an increased risk of **cardiovascular events** and **venous thromboembolism**, making it a less favored option compared to bisphosphonates.

Question 709: Which Selective Estrogen Receptor Modulator (SERM) is used in the treatment of Dysfunctional Uterine Bleeding (DUB)?

A. Clomiphene
B. Raloxifene
C. Ormiloxifene (Correct Answer)
D. Tamoxifen

Explanation: ***Correct: Ormiloxifene*** - Ormiloxifene is a **selective estrogen receptor modulator (SERM)** specifically approved and used for the management of **dysfunctional uterine bleeding (DUB)**. - It works by acting as an **estrogen antagonist on the endometrium**, which influences the endometrial lining to regulate bleeding patterns and **reduce menstrual blood loss**. - Marketed as **Sevista/Saheli** in India. *Incorrect: Clomiphene* - Clomiphene is primarily used as an **ovulation inducer** in women with infertility due to anovulation [1]. - It acts by blocking estrogen receptors in the hypothalamus, thereby increasing the secretion of gonadotropins [1]. - Not indicated for treatment of DUB. *Incorrect: Raloxifene* - Raloxifene is indicated for the prevention and treatment of **postmenopausal osteoporosis** and the reduction of invasive breast cancer risk in certain high-risk women [1][2]. - It has estrogen-agonist effects on bone and antagonist effects on breast and uterine tissue [1][2]. - Not used for management of DUB. *Incorrect: Tamoxifen* - Tamoxifen is widely used in the treatment of **estrogen receptor-positive breast cancer** in both pre- and postmenopausal women [1][2]. - It acts as an estrogen antagonist in breast tissue but has **estrogen-agonist effects on the endometrium**, which can cause endometrial hyperplasia or cancer [1][2]. - Not indicated for DUB treatment.

Question 710: Norgestimate in OC pills has the following advantage?

A. Reduces acne and hirsutism (Correct Answer)
B. May reduce the risk of venous thrombosis
C. Is generally more affordable than standard OC pills
D. May have cardiovascular benefits

Explanation: ***reduces acne and hirsutism*** - **Norgestimate** is a third-generation progestin known for its **low androgenic activity**, which helps to counteract the androgenic effects that can contribute to acne and hirsutism when combined with estrogen. - By minimizing androgenic side effects, norgestimate-containing oral contraceptive pills (OCPs) can improve skin conditions such as **acne** and unwanted hair growth (**hirsutism**), making them a preferred choice for patients with these concerns. *May reduce the risk of venous thrombosis* - While some progestins are associated with varying risks of venous thrombosis, norgestimate does not inherently **reduce** this risk compared to other progestins; in fact, all combined OCPs carry some increased risk. - The risk of **venous thromboembolism (VTE)** is primarily influenced by the estrogen component and the specific type and dose of progestin, but norgestimate is not specifically noted for reducing this risk. *Is generally more affordable than standard OC pills* - The cost of OCPs can vary widely based on brand, generic availability, and insurance coverage; norgestimate-containing pills are not inherently more affordable than other standard OCPs. - In some cases, newer formulations or brand-name versions of norgestimate-containing pills may even be **more expensive** than older, generic alternatives. *May have cardiovascular benefits* - Combined oral contraceptives, including those with norgestimate, generally do not offer **cardiovascular benefits** and may even increase the risk of cardiovascular events, particularly in women with pre-existing risk factors. - Long-term use of OCPs, especially in smokers or those with hypertension, can elevate the risk of conditions like **myocardial infarction** and **stroke**, rather than providing benefits.

Practice by Chapter

Hypothalamic and Pituitary Hormones

Practice Questions

Thyroid Drugs and Antithyroid Agents

Practice Questions

Insulin and Oral Hypoglycemic Agents

Practice Questions

Adrenocorticosteroids

Practice Questions

Sex Hormones: Estrogens and Progestins

Practice Questions

Androgens and Anabolic Steroids

Practice Questions

Hormonal Contraceptives

Practice Questions

Drugs Affecting Calcium Metabolism

Practice Questions

Drugs for Osteoporosis

Practice Questions

Pharmacological Management of Obesity

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free